stockrowTarsus Pharmaceuticals, Inc.
TARS Healthcare Biotechnology
Tarsus Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $451.4 million, up 146.7% from fiscal 2024.
- Revenue
- +63.9%
- EPS
- −4,699.1%
- Free cash flow
- −144.1%
- Total debt
- +0.90%
Quarter to September 2026, against a year earlier
Follow TARS
Alert me
Tarsus Pharmaceuticals, Inc. (TARS) Return on assets
Tarsus Pharmaceuticals, Inc.'s return on assets over the twelve months to 30 September 2026 was −135.0%, down 120.9 percentage points from fiscal 2025 (−14.1%). Over the past ten years it has ranged from −110.4% (fiscal 2018) to −7.88% (fiscal 2021); the current reading is higher than 88% of that period. That is below the Biotechnology industry median of −45.6% and below the Healthcare sector median of −29.3%.
Return on assets, annual
Embed this chart
Annual newest first
| Period | Return on assets | Change (points) |
|---|---|---|
| FY2025 | −14.1% | 21.83 |
| FY2024 | −36.0% | 19.12 |
| FY2023 | −55.1% | (24.56) |
| FY2022 | −30.5% | (22.65) |
| FY2021 | −7.88% | 15.40 |
| FY2020 | −23.3% | (7.89) |
| FY2019 | −15.4% | 95.03 |
| FY2018 | −110.4% | — |
Against its own ten years
Return on assets against peers
| Company | Return on assets |
|---|---|
| ACAD ACADIA Pharmaceuticals Inc. compare | 23.2% |
| TLX Telix Pharmaceuticals Limited compare | 0.00% |
| ELVN Enliven Therapeutics, Inc. compare | −15.0% |
| DNLI Denali Therapeutics Inc. compare | −27.2% |
| CELC Celcuity, Inc. compare | −44.8% |
| VRDN Viridian Therapeutics, Inc. compare | −56.5% |
| DYN Dyne Therapeutics, Inc. compare | −60.3% |
| VKTX Viking Therapeutics, Inc. compare | −73.1% |
| TARS Tarsus Pharmaceuticals, Inc. | −135.0% |
| Biotechnology industry median | −45.6% |
| Healthcare sector median | −29.3% |
| Market median | 0.00% |
What Return on assets is
ROA tells an investor how much profit a company earns for shareholders from the assets it uses to run its business.
Annual: Net Income Allotted to Shareholders ÷ Average Assets; TTM: Net Income Allotted to Shareholders ÷ Average Assets (latest quarter)
More on TARS
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement